Regulation of Tumor Initiation by the Mitochondrial Pyruvate Carrier

Although metabolic adaptations have been demonstrated to be essential for tumor cell proliferation, the metabolic underpinnings of tumor initiation are poorly understood. We found that the earliest stages of colorectal cancer (CRC) initiation are marked by a glycolytic metabolic signature, including...

Full description

Saved in:
Bibliographic Details
Published inCell metabolism Vol. 31; no. 2; pp. 284 - 300.e7
Main Authors Bensard, Claire L., Wisidagama, Dona R., Olson, Kristofor A., Berg, Jordan A., Krah, Nathan M., Schell, John C., Nowinski, Sara M., Fogarty, Sarah, Bott, Alex J., Wei, Peng, Dove, Katja K., Tanner, Jason M., Panic, Vanja, Cluntun, Ahmad, Lettlova, Sandra, Earl, Christian S., Namnath, David F., Vázquez-Arreguín, Karina, Villanueva, Claudio J., Tantin, Dean, Murtaugh, L. Charles, Evason, Kimberley J., Ducker, Gregory S., Thummel, Carl S., Rutter, Jared
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 04.02.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Although metabolic adaptations have been demonstrated to be essential for tumor cell proliferation, the metabolic underpinnings of tumor initiation are poorly understood. We found that the earliest stages of colorectal cancer (CRC) initiation are marked by a glycolytic metabolic signature, including downregulation of the mitochondrial pyruvate carrier (MPC), which couples glycolysis and glucose oxidation through mitochondrial pyruvate import. Genetic studies in Drosophila suggest that this downregulation is required because hyperplasia caused by loss of the Apc or Notch tumor suppressors in intestinal stem cells can be completely blocked by MPC overexpression. Moreover, in two distinct CRC mouse models, loss of Mpc1 prior to a tumorigenic stimulus doubled the frequency of adenoma formation and produced higher grade tumors. MPC loss was associated with a glycolytic metabolic phenotype and increased expression of stem cell markers. These data suggest that changes in cellular pyruvate metabolism are necessary and sufficient to promote cancer initiation. [Display omitted] •Intestinal tumors exhibit low MPC expression•MPC inactivation is sufficient to promote intestinal tumor formation in mice and flies•MPC overexpression in the fly is sufficient to prevent oncogene-induced tumorigenesis•MPC expression correlates negatively with expression of Wnt/β-catenin target genes A hallmark of cancer is altered metabolism in tumor cells; however, it is unclear whether cancer initiation also requires metabolic changes. Bensard et al. demonstrate that constitutive enforcement of a glycolytic program through inactivation of the mitochondrial pyruvate carrier (MPC) is necessary and sufficient to drive intestinal tumor formation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current Address: Department of Surgery and Perioperative Care, Dell Medical School, University of Texas, Austin, TX 78712, USA
CLB and KAO designed the mouse experimental strategy with input from JCS, PW, AC, KD, JMT, CJV, DT, LCM, KJE and JR. DRW designed and performed the fly experiments with input and supervision from CST. CLB and KAO, with help from CSE and DFN, performed MPC1 mouse homeostatic experiments and data analysis. CLB, with help from CSE and DFN, performed all tumor initiation experiments and data analysis from mouse studies. CLB, KAO, NMK, KJE, and LCM performed histological staining and imaging of mouse tissue. CLB, SF, and VP quantified tumor proliferation indices. KJE and CLB assessed all histology. SMN performed protein validation by immunoblots. KVA and DT contributed supplemental samples. CLB, CSE, DFN, and KAO maintained mouse colony. CLB, JAB, and AJB designed human gene expression experiment. CLB with input from GSD, AC, and JR designed the metabolomics experiments and collected all data with assistance from SF, PW, KD, AC, SL, and AJB. GSD performed all metabolomic experiments and data analysis. JAB and AJB designed and performed all bioinformatics analyses. CLB and DRW, with contributions from SF, KAO, JAB and AJB, made all figures. CLB, DRW, CST and JR wrote the manuscript with input from NMK, KJE, SF, DT, and SMN. All work was performed at the University of Utah.
These authors contributed equally to this work
Current Address: Department of Medicine, Massachusetts General Hospital, Boston MA, 02114
Author contributions
ISSN:1550-4131
1932-7420
1932-7420
DOI:10.1016/j.cmet.2019.11.002